生存率-话题@MedSci

#生存率#

482篇内容 | 3062人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1256725, encodeId=12bf1256e2506, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=2019 ESMO：CDK4 / 6抑制作用可提高HR + / HER2-晚期乳腺癌患者的生存率, objectType=article, longId=180364, objectId=f1771803649f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1771803649f, replyNumber=0, likeNumber=70, createdTime=2019-10-02, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1771803649f, moduleTitle=2019 ESMO：CDK4 / 6抑制作用可提高HR + / HER2-晚期乳腺癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1771803649f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256724, encodeId=ccc01256e2430, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=JAMA Oncol:免疫治疗前使用抗生素，或显著降低癌症患者的生存率, objectType=article, longId=179907, objectId=19ba1e9907cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19ba1e9907cd, replyNumber=0, likeNumber=61, createdTime=2019-09-24, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19ba1e9907cd, moduleTitle=JAMA Oncol:免疫治疗前使用抗生素，或显著降低癌症患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19ba1e9907cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256723, encodeId=9ff91256e239e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=J Gastroenterology：治疗顽固性腹水可以减轻肌肉质量的减少并提高失代偿期肝硬化患者的生存率, objectType=article, longId=179695, objectId=fd8d1e969584, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd8d1e969584, replyNumber=0, likeNumber=117, createdTime=2019-09-20, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd8d1e969584, moduleTitle=J Gastroenterology：治疗顽固性腹水可以减轻肌肉质量的减少并提高失代偿期肝硬化患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd8d1e969584)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256722, encodeId=56481256e222b, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=J Hepatology：普伐他汀与索拉非尼联合治疗并未改善晚期肝细胞癌的生存率, objectType=article, longId=179354, objectId=69551e93547e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69551e93547e, replyNumber=0, likeNumber=61, createdTime=2019-09-14, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69551e93547e, moduleTitle=J Hepatology：普伐他汀与索拉非尼联合治疗并未改善晚期肝细胞癌的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69551e93547e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256721, encodeId=9c331256e212f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=JACC：外科手术不会改善孤立性三尖瓣反流患者的生存率, objectType=article, longId=178441, objectId=d6181e84414a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6181e84414a, replyNumber=0, likeNumber=79, createdTime=2019-09-01, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6181e84414a, moduleTitle=JACC：外科手术不会改善孤立性三尖瓣反流患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6181e84414a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256720, encodeId=9b901256e2004, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=卡介苗的短缺导致了膀胱癌生存率的下降, objectType=article, longId=177570, objectId=72fa1e757081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72fa1e757081, replyNumber=0, likeNumber=59, createdTime=2019-08-15, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72fa1e757081, moduleTitle=卡介苗的短缺导致了膀胱癌生存率的下降, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72fa1e757081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256719, encodeId=b00d1256e1926, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=Chest：肺栓塞引起的院外心脏骤停复苏期间溶栓治疗可提高30天的生存率, objectType=article, longId=176845, objectId=66331e68459a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66331e68459a, replyNumber=0, likeNumber=69, createdTime=2019-08-06, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66331e68459a, moduleTitle=Chest：肺栓塞引起的院外心脏骤停复苏期间溶栓治疗可提高30天的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66331e68459a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256718, encodeId=a9911256e1847, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=晚期乳腺癌：Verzenio显著提高了HR阳性/HER2阴性患者的生存率, objectType=article, longId=176547, objectId=81d61e65477b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81d61e65477b, replyNumber=0, likeNumber=70, createdTime=2019-08-01, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81d61e65477b, moduleTitle=晚期乳腺癌：Verzenio显著提高了HR阳性/HER2阴性患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81d61e65477b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256717, encodeId=9ab31256e17a9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=J Hepatology：成功治疗早期肝细胞癌后的直接作用抗病毒药物可改善HCV肝硬化患者的生存率, objectType=article, longId=176003, objectId=fb721e600347, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb721e600347, replyNumber=0, likeNumber=68, createdTime=2019-07-24, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb721e600347, moduleTitle=J Hepatology：成功治疗早期肝细胞癌后的直接作用抗病毒药物可改善HCV肝硬化患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb721e600347)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256716, encodeId=0b1f1256e169a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=Lancet Oncol：满足 vs 不满足USPSTF筛查标准的肺癌患者，5年生存率相似, objectType=article, longId=174580, objectId=87fc1e4580c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87fc1e4580c3, replyNumber=0, likeNumber=59, createdTime=2019-07-02, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87fc1e4580c3, moduleTitle=Lancet Oncol：满足 vs 不满足USPSTF筛查标准的肺癌患者，5年生存率相似, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87fc1e4580c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256715, encodeId=364c1256e151d, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=与索拉非尼相比，Opdivo无法显著提高肝癌患者的生存率, objectType=article, longId=172162, objectId=ddb51e2162bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb51e2162bf, replyNumber=0, likeNumber=50, createdTime=2019-06-27, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb51e2162bf, moduleTitle=与索拉非尼相比，Opdivo无法显著提高肝癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb51e2162bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256714, encodeId=20d81256e1456, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=研究5年随访结果更新，初治PD-L1≥50%的晚期NSCLC 5年生存率达29.6%, objectType=article, longId=168262, objectId=258116826276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=258116826276, replyNumber=0, likeNumber=58, createdTime=2019-06-14, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=258116826276, moduleTitle=研究5年随访结果更新，初治PD-L1≥50%的晚期NSCLC 5年生存率达29.6%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=258116826276)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256713, encodeId=8f091256e138e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=这种病，60%会被当成胃病，5年生存率低于5%！, objectType=article, longId=168177, objectId=b57d1681e7ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b57d1681e7ad, replyNumber=0, likeNumber=134, createdTime=2019-06-13, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b57d1681e7ad, moduleTitle=这种病，60%会被当成胃病，5年生存率低于5%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b57d1681e7ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256712, encodeId=d91d1256e123a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=攻坚克难 Lancet大数据显示我国癌症生存率有显著提升！, objectType=article, longId=167765, objectId=ad7a16e76525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad7a16e76525, replyNumber=0, likeNumber=74, createdTime=2019-06-07, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad7a16e76525, moduleTitle=攻坚克难 Lancet大数据显示我国癌症生存率有显著提升！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad7a16e76525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256711, encodeId=8f871256e1186, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率, objectType=article, longId=166645, objectId=66b1166645d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66b1166645d2, replyNumber=0, likeNumber=58, createdTime=2019-05-24, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66b1166645d2, moduleTitle=Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66b1166645d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256710, encodeId=c12e1256e1095, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=癌症生存率整体大幅提高，这个垫底的类型希望在哪儿？, objectType=article, longId=165871, objectId=92911658e1cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92911658e1cd, replyNumber=0, likeNumber=59, createdTime=2019-05-13, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92911658e1cd, moduleTitle=癌症生存率整体大幅提高，这个垫底的类型希望在哪儿？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92911658e1cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256709, encodeId=37c01256e0958, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=Eur Heart J：心脏再同步治疗患者的长期生存率和晚期心源性猝死, objectType=article, longId=165581, objectId=cfa8165581dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfa8165581dc, replyNumber=0, likeNumber=101, createdTime=2019-05-09, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfa8165581dc, moduleTitle=Eur Heart J：心脏再同步治疗患者的长期生存率和晚期心源性猝死, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfa8165581dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256708, encodeId=e8e01256e08f4, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=JACC：生活方式、HbA1c等风险因素控制可改善患者生存率, objectType=article, longId=165325, objectId=9a331653250b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a331653250b, replyNumber=0, likeNumber=81, createdTime=2019-05-05, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a331653250b, moduleTitle=JACC：生活方式、HbA1c等风险因素控制可改善患者生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a331653250b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256707, encodeId=856f1256e07ec, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=Ann Surg:全程新辅助治疗（TNT）可提高晚期胰腺癌生存率, objectType=article, longId=164775, objectId=ee1c164e7531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee1c164e7531, replyNumber=0, likeNumber=83, createdTime=2019-04-23, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee1c164e7531, moduleTitle=Ann Surg:全程新辅助治疗（TNT）可提高晚期胰腺癌生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee1c164e7531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1256706, encodeId=f4551256e0694, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, objectTitle=JACC：低流量、低梯度和高梯度主动脉瓣狭窄患者TAVR后的1年生存率, objectType=article, longId=164669, objectId=c162164669ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c162164669ef, replyNumber=0, likeNumber=64, createdTime=2019-04-22, rootId=0, userName=guoyibin, userId=6a6043, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c162164669ef, moduleTitle=JACC：低流量、低梯度和高梯度主动脉瓣狭窄患者TAVR后的1年生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c162164669ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存率

2020-05-29

guoyibin (审核中...)

前往app查看评论内容

#生存率#

2019 ESMO：CDK4 / 6抑制作用可提高HR + / HER2-晚期乳腺癌患者的生存率

2019-10-02

guoyibin (审核中...)

前往app查看评论内容

#生存率#

JAMA Oncol:免疫治疗前使用抗生素，或显著降低癌症患者的生存率

2019-09-24

guoyibin (审核中...)

前往app查看评论内容

#生存率#

J Gastroenterology：治疗顽固性腹水可以减轻肌肉质量的减少并提高失代偿期肝硬化患者的生存率

2019-09-20

guoyibin (审核中...)

前往app查看评论内容

#生存率#

J Hepatology：普伐他汀与索拉非尼联合治疗并未改善晚期肝细胞癌的生存率

2019-09-14

guoyibin (审核中...)

前往app查看评论内容

#生存率#

JACC：外科手术不会改善孤立性三尖瓣反流患者的生存率

2019-09-01

guoyibin (审核中...)

前往app查看评论内容

#生存率#

卡介苗的短缺导致了膀胱癌生存率的下降

2019-08-15

guoyibin (审核中...)

前往app查看评论内容

#生存率#

Chest：肺栓塞引起的院外心脏骤停复苏期间溶栓治疗可提高30天的生存率

2019-08-06

guoyibin (审核中...)

前往app查看评论内容

#生存率#

晚期乳腺癌：Verzenio显著提高了HR阳性/HER2阴性患者的生存率

2019-08-01

guoyibin (审核中...)

前往app查看评论内容

#生存率#

J Hepatology：成功治疗早期肝细胞癌后的直接作用抗病毒药物可改善HCV肝硬化患者的生存率

2019-07-24

guoyibin (审核中...)

前往app查看评论内容

#生存率#

Lancet Oncol：满足 vs 不满足USPSTF筛查标准的肺癌患者，5年生存率相似

2019-07-02

guoyibin (审核中...)

前往app查看评论内容

#生存率#

与索拉非尼相比，Opdivo无法显著提高肝癌患者的生存率

2019-06-27

guoyibin (审核中...)

前往app查看评论内容

#生存率#

研究5年随访结果更新，初治PD-L1≥50%的晚期NSCLC 5年生存率达29.6%

2019-06-14

guoyibin (审核中...)

前往app查看评论内容

#生存率#

这种病，60%会被当成胃病，5年生存率低于5%！

2019-06-13

guoyibin (审核中...)

前往app查看评论内容

#生存率#

攻坚克难 Lancet大数据显示我国癌症生存率有显著提升！

2019-06-07

guoyibin (审核中...)

前往app查看评论内容

#生存率#

Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率

2019-05-24

guoyibin (审核中...)

前往app查看评论内容

#生存率#

癌症生存率整体大幅提高，这个垫底的类型希望在哪儿？

2019-05-13

guoyibin (审核中...)

前往app查看评论内容

#生存率#

Eur Heart J：心脏再同步治疗患者的长期生存率和晚期心源性猝死

2019-05-09

guoyibin (审核中...)

前往app查看评论内容

#生存率#

JACC：生活方式、HbA1c等风险因素控制可改善患者生存率

2019-05-05

guoyibin (审核中...)

前往app查看评论内容

#生存率#

Ann Surg:全程新辅助治疗（TNT）可提高晚期胰腺癌生存率

2019-04-23

guoyibin (审核中...)

前往app查看评论内容

#生存率#

JACC：低流量、低梯度和高梯度主动脉瓣狭窄患者TAVR后的1年生存率

2019-04-22

科室
- - 订阅+
  - 更多科室
工具
服务